Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A., PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis, «FUTURE ONCOLOGY», 2021, 17, pp. 4415 - 4424 [articolo]
Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2021, 160, Article number: 103302, pp. 1 - 5 [articolo]
Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [articolo]
Minari R.; Bonatti F.; Mazzaschi G.; Dodi A.; Facchinetti F.; Gelsomino F.; Cinquegrani G.; Squadrilli A.; Bordi P.; Buti S.; Bersanelli M.; Leonetti A.; Cosenza A.; Ferri L.; Rapacchi E.; Quaini F.; Ardizzoni A.; Tiseo M., PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors, «TUMORI», 2021, 00(0), pp. 1 - 9 [articolo]
Gelsomino F.; Facchinetti F.; Sisi M.; Zielli T.; Tiseo M.; Ardizzoni A., PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination, «IMMUNOTHERAPY», 2021, 13, pp. 363 - 369 [articolo]
Pellegrino B.; Cavanna L.; Boggiani D.; Zamagni C.; Frassoldati A.; Schirone A.; Caldara A.; Rocca A.; Gori S.; Piacentini F.; Berardi R.; Brandes A.A.; Foglietta J.; Villa F.; Todeschini R.; Tognetto M.; Naldi N.; Bortesi B.; Montemurro F.; Ardizzoni A.; Boni L.; Musolino A., Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), «ESMO OPEN», 2021, 6, Article number: 100019, pp. 1 - 8 [articolo]Open Access
Brocchi S.; Parmeggiani A.; Gaudiano C.; Balacchi C.; Renzulli M.; Brandi N.; Dall'olio F.G.; Rihawi K.; Ardizzoni A.; Golfieri R., Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series, «ACTA GASTRO-ENTEROLOGICA BELGICA», 2021, 84, pp. 497 - 499 [articolo]
Ardizzoni A.; Azevedo S.; Rubio-Viqueira B.; Rodriguez-Abreu D.; Alatorre-Alexander J.; Smit H.J.M.; Yu J.; Syrigos K.; Trunzer K.; Patel H.; Tolson J.; Cardona A.; Perez-Moreno P.D.; Newsom-Davis T., Primary results from TAIL: A global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2021, 9, Article number: e001865, pp. 1 - 10 [articolo]Open Access
Mollica, Veronica; Rizzo, Alessandro; Tassinari, Elisa; Giunchi, Francesca; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study, «ANTI-CANCER DRUGS», 2021, 32, pp. 74 - 81 [articolo]
De Giglio A.; Di Federico A.; Gelsomino F.; Ardizzoni A., Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database, «LUNG CANCER», 2021, 161, pp. 18 - 25 [articolo]
Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Boni L.; Ardizzoni A., Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis, «JTO CLINICAL AND RESEARCH REPORTS», 2021, 2, Article number: 100214, pp. 1 - 10 [articolo]Open Access
Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F., Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review, «FUTURE ONCOLOGY», 2021, 17, pp. 2671 - 2681 [articolo]
Rizzo A.; Dall'Olio F.G.; Altimari A.; Giunchi F.; Ardizzoni A., Role of PD-L1 assessment in advanced NSCLC: does it still matter?, «ANTI-CANCER DRUGS», 2021, 32, pp. 1084 - 1085 [articolo]
Federico, Alessandro Di; Gelsomino, Francesco; De Biase, Dario; Ardizzoni, Andrea, Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation, «CLINICAL LUNG CANCER», 2021, 000, pp. 1 - 2 [articolo]
Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A., Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution, «ANTI-CANCER DRUGS», 2021, 32, pp. 755 - 757 [articolo]Open Access
